New MYO5B gene mutation detected in man with PFIC type 10
A combination of two mutations in the MYO5B gene, including one that has not been previously reported, was the likely cause of a mild form…
News
Diabetes drug dapagliflozin shows benefits for MASH in Phase 3 trial
Daily treatment with the diabetes medication dapagliflozin eased disease severity for people with metabolic dysfunction-associated steatohepatitis (MASH), a severe form of fatty liver disease,…
Combined blood measure may detect biliary atresia in newborns
Combining the levels of two liver damage markers, obtained from standard blood tests, can accurately discriminate infants with biliary atresia from those without the…
Clinical testing begins for vaccine to treat hepatitis B
Astrivax Therapeutics has begun clinical testing of AVX70371, an experimental vaccine designed to treat hepatitis B. “Starting clinical development with AVX70371 is the first…
Trial of golexanolone for PBC cognitive symptoms to resume
A Phase 1b/2a clinical trial of golexanolone, Umecrine Cognition’s candidate therapy for cognitive symptoms and fatigue related to primary biliary cholangitis (PBC), will resume…
ICP linked to lower levels of vitamin K in small study
Women with intrahepatic cholestasis of pregnancy (ICP), the most common liver complication during pregnancy, are significantly more likely to have reduced blood levels of…
Scientists call for more efforts to diagnose liver disease MASH
An international team of scientists called for more efforts to diagnose metabolic dysfunction-associated steatohepatitis (MASH), a severe form of fatty liver disease, arguing that…
Gene therapy shows promise for Alagille liver disease: Mouse study
The use of an experimental, one-time gene therapy in a mouse model of Alagille syndrome increased the number of bile ducts — tubes that…
AusperBio raises $50M to advance AHB-137 for chronic hepatitis B
AusperBio raised $50 million to advance the development of chronic hepatitis B treatment AHB-137. The company said the funding will help it launch Phase…
FDA to review linerixibat for PBC-related itching
The U.S. Food and Drug Administration (FDA) has accepted for review GSK’s application seeking the approval of its oral treatment linerixibat for intense itching, or…
